MCK · Mckesson Corp

Track MCK — free

$1,102.81 +25.76 (+2.39%) At close · Nov 13

S&P 500 member Russell 1000 member Rebalance outlook locked

Market Cap

$127.33B

115.46M

Volume · Nov 13 528.43K Avg daily vol (3M) 804.4K

Up next

Next earnings call

Feb 3, 2027 Est · unconfirmed · in 11 wks

Q2 2027 earnings call transcript

call held Nov 4, 2026

Play latest call

Latest documents

what the company just published, in one sentence each

2026

Nov 4

Earnings call

Q2 2027 earnings call AI summary on its way

Nov 4

Quarterly report 10-Q FY2027 Q2, ended Sep 30

Revenue rises 8%; Precision Medicine acquired for $2.25 billion

McKesson reported revenue up 8% and gross profit up 12% for the six months ended September 30, 2026. In early November, it completed Precision Medicine for approximately $2.25 billion and acquired a controlling Spectrum Vision interest for approximately $525 million.

Revenue $110.96B ▲ 7.6% Net income $1.22B ▲ 9.7% Diluted EPS $10.44 ▲ 17.0%

Read from the MD&A section

3 source passages

For the six months ended September 30, 2026 compared to the prior year, revenues increased by 8%, gross profit increased by 12%, total operating expenses increased by 8%, and other income, net increased by 2%. the acquisition of Precision Medicine Group, LLC (“Precision Medicine”), a global provider of clinical research and biopharma commercialization services, for cash of approximately $2.25 billion (subject to customary post-closing adjustments). the acquisition of a controlling interest in Spectrum Vision Partners (“Spectrum Vision”), a provider of ophthalmology and retina management services, for approximately $525 million (subject to customary post- closing adjustments). Open the document at this passage

Nov 4

Current report 8-K

Financial results AI summary on its way

Oct 6

Current report 8-K

Regulation FD disclosure

McKesson and CD&R agreed to acquire Option Care Health for $32.05 per share, valuing it at approximately $5.8 billion; McKesson will invest approximately $1.4 billion for approximately 49%. Expected to close in the first half of calendar year 2027.

Sep 14

Investor event

Morgan Stanley 24th Annual Global Healthcare Conference AI summary on its way

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

View all 125 metrics

Revenue (TTM)

$418.79B

Trailing 12 months

Net income (TTM)

$4.70B

Trailing 12 months

Revenue growth YoY

+7.6%

Year over year

Operating margin

1.6%

Trailing 12 months

P / E (TTM)

28.4

Trailing earnings · reciprocal yield 3.5%

FCF yield

5.6%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

−$2.67B

Latest balance sheet

Dividend yield

0.3%

Trailing 12 months

Shares change YoY

-6.2%

Year over year · fewer shares

Price change (1Y)

+30.3%

Trailing year

Short interest

1.7%

Latest settlement · 2.9 days to cover

View all 125 metrics

Quarterly results

Revenue Net income Net loss

▲17.8% $95.29B $879.00M '25 Q3 ▲18.9% $90.82B $1.26B '25 Q4* ▲23.4% $97.83B $784.00M '26 Q1 ▲10.1% $103.15B $1.11B '26 Q2 ▲11.4% $106.16B $1.19B '26 Q3 ▲6% $96.30B $1.68B '26 Q4* ▲7.7% $105.38B $614.00M '27 Q1 LATEST ▲7.6% $110.96B $1.22B '27 Q2

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q2 FY27 earnings call · Nov 4, 2026

Q2 FY27

TL;DR. McKesson reported 8% revenue growth and 18% adjusted EPS growth, raised fiscal 2027 adjusted EPS guidance to $45.60 to $46.40, generated $2.9 billion of quarterly free cash flow, and led growth with North American Pharmaceutical and Oncology & Multispecialty. Medical-Surgical Solutions profit declined, interest expense and corporate expenses are expected at the high end of their ranges, and the Option Care investment remains subject to closing conditions.

Bullish

+ Consolidated revenue grew 8% to $111 billion, led by North American Pharmaceutical and Oncology & Multispecialty.
+ Adjusted earnings per diluted share increased 18% to $11.68.
+ McKesson raised its fiscal 2027 adjusted EPS guidance to $45.60 to $46.40 from $44.20 to $45.00.
+ McKesson generated $2.9 billion of quarterly free cash flow.
+ The Precision Medicine Group acquisition is expected to be accretive, contributing approximately 10 to 20 cents of adjusted EPS in fiscal 27 and approximately $1.60 to $1.80 by the end of year three.
+ McKesson extended its CVS Health pharmaceutical distribution partnership through June 2032.

Bearish

− Medical-Surgical Solutions adjusted operating profit decreased 10% to $225 million.
− Medical-Surgical Solutions operating profit is expected to range from a 4% decline to FLAX in fiscal 2027.
− Interest expense is expected at the high end of $380 to $420 million because of higher borrowing rates associated with financing activities.
− Corporate expenses are expected at the high end of the $580 to $640 million range.
− The Option Care Health investment is subject to closing conditions and the current outlook does not contemplate contributions from Option Care Health.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate

Market backdrop VIX 19.3 · elevated Equity put/call 0.63

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +26%

above

Price vs 50-day avg +15%

above

RSI (14) 75

overbought

MACD trend Positive

52-week position 100%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +10%

trailing

6-month return +46%

trailing

YTD return +34%

this year

Relative strength +46%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $955 › 200d $874 — 50d above 200d

Institutional flow Distributing

1,888 of 2,038 funds reported for Sep 30 · net -3.9M sh shares · +154 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

1.72% of shares out · ▼ -13.4% MoM · 2.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

2,038 holders — near 3-yr high, broad support

Squeeze score 49

elevated · 0–100

Fundamentals

Excellent

Revenue growth +3%

Y/Y

Gross margin 13%

expanding

EPS growth +49%

Y/Y

Free cash flow $5.7B

Balance sheet $2.5B

net debt

Quant / Vol

risk profile

Moderate

Volatility 32%

annualized · 1-yr

Max drawdown −27%

past year

ATR 2.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Aug 5, 2026

Fiscal 27 adjusted earnings per share outlook · fiscal 27 Non-GAAP Raised $44.20 – $45.00

May 7, 2026 $43.80 – $44.60 Aug 5, 2026 $44.20 – $45.00

North American Pharmaceutical revenue growth · fiscal 27 Initiated 4% – 8%

Oncology and multi-specialty revenue growth · fiscal 27 Initiated 14.5% – 18.5%

Oncology and multi-specialty operating profit growth · fiscal 27 Initiated 13.5% – 17.5%

Prescription Technology Solutions revenue growth · fiscal 27 Initiated 2.5% – 6.5%

Prescription Technology Solutions operating profit growth · fiscal 27 Initiated 11% – 15%

Corporate expenses · fiscal 27 Maintained $580M – $640M

May 7, 2026 $580M – $640M Aug 5, 2026 $580M – $640M

Interest expense · fiscal 27 Maintained $380M – $420M

May 7, 2026 $380M – $420M Aug 5, 2026 $380M – $420M

Effective tax rate · fiscal 27 Raised 18% – 19%

May 7, 2026 17% – 19% Aug 5, 2026 18% – 19%

Free cash flow · fiscal 27 Maintained $4.5B – $4.9B

May 7, 2026 $4.5B – $4.9B Aug 5, 2026 $4.5B – $4.9B

Share repurchases · fiscal 27 Maintained $5B

May 7, 2026 $5B Aug 5, 2026 $5B

Income attributable to non-controlling interest · fiscal 27 Maintained $295M – $325M

May 7, 2026 $295M – $325M Aug 5, 2026 $295M – $325M

Previous outlook earlier release · from the Earnings Call filed May 7, 2026

Still-open targets the latest release did not restate under the same label.

Long-term adjusted earnings per diluted share growth · long-term 13% – 16%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 2 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+26% Bullish

Price vs 50-day avg

+15% Bullish

RSI (14)

75 Bearish

MACD trend

Positive Bullish

52-week position

100% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $955 › 200d $874 — 50d above 200d

Institutional flow Distributing

1,888 of 2,038 funds reported for Sep 30 · net -3.9M sh shares · +154 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

1.72% of shares out · ▼ -13.4% MoM · 2.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

2,038 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $725 Now $1,103 · 100% Range high $1,103

vs 200-day avg +26% vs 50-day avg +15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted Earnings non-GAAP	$1.18B	Q1 FY27	—
GAAP → non-GAAP reconciliation GAAP Net income attributable to McKesson Corporation 614M +74M Amortization of acquisition-related intangibles +108M Transaction-related expenses and adjustments -2M LIFO inventory-related adjustments -6M Gains from antitrust legal settlements +136M Restructuring, impairment, and related charges, net -34M Claims and litigation charges, net -6M Other adjustments, net -64M Income tax effect on pre-tax adjustments +363M Net income attributable to noncontrolling interests effect on pre-tax adjustments and redeemable noncontrolling interests adjust = Adjusted Earnings 1.18B
Adjusted Earnings per Diluted Share non-GAAP	$9.93	Q1 FY27	—
GAAP → non-GAAP reconciliation GAAP Earnings per diluted common share attributable to McKesson Corporation $5.15 +$0.41 Amortization of acquisition-related intangibles +$3.85 Transaction-related expenses and adjustments -$0.02 LIFO inventory-related adjustments -$0.03 Gains from antitrust legal settlements +$0.82 Restructuring, impairment, and related charges, net -$0.21 Claims and litigation charges, net -$0.04 Other adjustments, net = Adjusted Earnings per Diluted Share $9.93
Adjusted Segment Operating Profit - Medical-Surgical Solutions non-GAAP	$195M	Q1 FY27	—
GAAP → non-GAAP reconciliation GAAP Medical-Surgical Solutions operating profit (GAAP) 122M +73M Adjustments = Adjusted Segment Operating Profit - Medical-Surgical Solutions 195M
Adjusted Segment Operating Profit - North American Pharmaceutical non-GAAP	$894M	Q1 FY27	—
GAAP → non-GAAP reconciliation GAAP North American Pharmaceutical operating profit (GAAP) 903M -9M Adjustments = Adjusted Segment Operating Profit - North American Pharmaceutical 894M
Adjusted Segment Operating Profit - Oncology & Multispecialty non-GAAP	$405M	Q1 FY27	—
GAAP → non-GAAP reconciliation GAAP Oncology & Multispecialty operating profit (GAAP) 325M +80M Adjustments = Adjusted Segment Operating Profit - Oncology & Multispecialty 405M
Adjusted Segment Operating Profit - Prescription Technology Solutions non-GAAP	$303M	Q1 FY27	—
GAAP → non-GAAP reconciliation GAAP Prescription Technology Solutions operating profit (GAAP) 226M +77M Adjustments = Adjusted Segment Operating Profit - Prescription Technology Solutions 303M
Free Cash Flow non-GAAP	$372M	Q1 FY27	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Distribution — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
MCK Mckesson Corp this stock	$127.33B	+34.4%	+3.1%	28.4	1.7%
COR Cencora, Inc.	$68.51B	+6.3%	+9.3%	26.7	1.7%
CAH Cardinal Health Inc	$64.97B	+36.8%	+14.2%	—	3.3%
HSIC Henry Schein Inc	$9.53B	+14.1%	+5.9%	23.6	8.5%
EBOSY EBOS Group Limited	$2.37B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

2,119

% held: 88.8%
Reported: 1,888 of 2,038
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

1,103

View

Short & Settlement

Short Interest Falling

Shares short

2.0M

Days to cover: 2.9d
Change: -308.1K sh

View

Short Volume

Short vol %

52%

As of: Nov 13, 2026

Short Total

View

Fails to Deliver

FTD shares

780

Value: $745.5K
As of: Oct 13, 2026

View

Off-Exchange

Off-exchange %

45.8%

Week of: Oct 5, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Buy

Member

Rick Larsen

Amount: $1.0K–$15.0K
Traded: Jul 8, 2026

View

Financials

Revenue (FY)

$403.4B

Net income (FY): $4.8B
EPS diluted: $38.38

View

Buybacks

Authorized

shares 2.3B

View

Filings

SEC Filings

Latest

10-Q

Filed: Nov 4, 2026
This year: 29

View

Proposed Sales

Value

$716.9K

Shares: 650
Filed: Nov 5, 2026

View

Earnings & Events

Webcasts

Last webcast

Nov 4, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
MCK	+4.0%	+9.8%	+46.2%	+10.9%	+34.4%
SPY	+2.6%	-1.2%	+0.5%	-0.2%	+10.6%
vs SPY	+1.4%	+10.9%	+45.7%	+11.1%	+23.8%

Capital returns

Latest dividend

$0.94 / share · ex Sep 1, 2026

Declared · upcoming

$0.94 / share · ex Dec 1, 2026

Raised 14.6%

Paid (TTM)

$3.40 / share · 4 payouts

Dividend yield (TTM, derived)

0.31%

Full dividend history

Buyback program · as of May 31, 2026

Authorized

shares 2.30B

Spent (derived)

—

Remaining

—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 927653 CUSIP 58155Q103 13F (30d) 1651 filings 1559 filers Visit website Investor relations

MCK · Mckesson Corp

Price & Indicators

Up next

Latest documents

Metrics snapshot

Quarterly results

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns